ValuentumAd

Official PayPal Seal
Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for any changes.
May 3, 2014
Teva Pharma: Underpriced and Misunderstood
The generics pharma giant remains one of our top ideas.
Apr 30, 2014
Earnings from 3 Internet Giants: eBay, Facebook, and Twitter
Assessing the contribution of equity value from each distinct period of Valuentum’s three-stage discounted cash flow model is a good way to assess underlying intrinsic-value uncertainty.
Apr 29, 2014
Earnings from 8 Interesting Ideas
Let’s examine the recent earnings reports from 8 firms that you should know about.
Apr 25, 2014
Earnings from 15 Dividend Growth Giants
Let’s take a look at recent results from a number of big dividend payers.
Apr 23, 2014
Perhaps Nothing Stronger Than Aerospace
Boeing put up strong first-quarter results and showcased its massive backlog of unfulfilled orders.
Apr 22, 2014
Big News in Big Pharma
Pfizer is looking to scoop up AstraZeneca, Valeant and Ackman eye Allergan, Eli Lilly and Novartis strike a deal in animal health, and Novartis picks up GSK’s oncology portfolio.
Apr 21, 2014
Restaurant Industry Update
Let’s take a look at some key developments in the restaurant space.
Apr 20, 2014
The Cola Wars: Currency Headwinds Intensify; Snacks Looking Better
Pepsi is slightly better positioned in 2014, but we like Coca-Cola better.
Apr 17, 2014
Another New High for GE’s Industrial Backlog!
General Electric is taking its business to the next level.
Apr 14, 2014
Surveying First-Quarter Bank Performance
Wells Fargo dips back into subprime lending, JP Morgan reveals weakness across the board, and Citigroup holds the line.


The High Yield Dividend Newsletter, Best Ideas Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on this website are for information purposes only and should not be considered a solicitation to buy or sell any security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees, and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.